Clinical Trials Logo

Clinical Trial Summary

Phase 0/1 local application of the monoclonal antibody (Mab) sB24M in patients with purulent pyoderma (chronic ulcerative pyoderma) by injection into the affected areas. Monoclonal antibody (Mab) sB24 negatively regulates immune-inflammatory processes through CD47 / TNF-α Axis promotes epithelialization of damaged tissue.


Clinical Trial Description

This is an open-label Phase 0 trial that will enroll up to 10 participants with purulent pyoderma (chronic ulcerative pyoderma) by injecting 200 mg of the monoclonal antibody (Mab) sB24M into the areas affected by pyoderma. Monoclonal antibody (Mab) sB24 negatively regulates immune-inflammatory processes through CD47 / TNF-α Axis promotes epithelialization of damaged tissue. This study is a first-in-man since previously no Clinical Studies on the local application (injections) of monoclonal antibodies in pyoderma gangrenosum have been conducted. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04895566
Study type Interventional
Source SWISS BIOPHARMA MED GmbH
Contact
Status Completed
Phase Early Phase 1
Start date May 24, 2021
Completion date March 16, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT06092216 - Spesolimab in Pyoderma Gangrenosum Phase 2
Completed NCT03311464 - A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan Phase 3
Recruiting NCT04901325 - Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG) Phase 2
Completed NCT00791557 - Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease N/A
Terminated NCT02318914 - A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum Phase 3
Terminated NCT02315417 - An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum Phase 3
Completed NCT03137160 - An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum Phase 2
Not yet recruiting NCT05984654 - Autologous Platelet-Rich Plasma Therapy in the Treatment of Pyoderma Gangrenosum N/A
Withdrawn NCT04274166 - Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum Phase 2
Completed NCT01882504 - Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum Phase 2
Withdrawn NCT00730717 - Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum Phase 2
Completed NCT03971643 - Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum Phase 2
Not yet recruiting NCT04792957 - JAK-STAT Signaling Pathway in Pyoderma Gangrenosum
Not yet recruiting NCT05821374 - Deucravacitinib in PG Early Phase 1
Terminated NCT03072953 - Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum Phase 2
Recruiting NCT05120726 - A Novel Therapeutic Treatment of Pyoderma Gangrenosum Phase 4
Withdrawn NCT00690846 - Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum Phase 2
Completed NCT01965613 - A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum Phase 2
Recruiting NCT01952275 - Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases N/A
Completed NCT01302795 - Canakinumab for Pyoderma Gangrenosum Phase 2